胰高血糖素样肽-1 受体激动剂对前列腺癌的影响：综述。
Effect of glucagon-like peptide-1 receptor agonists on prostate cancer: A review.
机构信息
Linyi People's Hospital of Shandong Second Medical University, Weifang, Shandong, China.
Linyi People's Hospital, Linyi, Shandong, China.
出版信息
Medicine (Baltimore). 2024 Oct 11;103(41):e39956. doi: 10.1097/MD.0000000000039956.
Glucagon-like peptide-1 receptor agonist (GLP-1RA) is widely used in the treatment of type 2 diabetes mellitus (T2DM) for its significant hypoglycemic effect, weight loss and small side effects. Some studies have shown that GLP-1RA has an inhibitory effect on prostate cancer, and its application will produce adverse effects associated with an increased or decreased risk of some tumors. GLP-1R is widely expressed by various types of cells and tissues in the human body, so GLP-1RA has attracted wide clinical attention to the occurrence, development and prognosis of tumors, which brings more new directions and hopes for the treatment of prostate cancer. This paper describes the expression of glucagon-like peptide-1 receptor (GLP-1R) in prostate cancer and the effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) on prostate cancer.
胰高血糖素样肽-1 受体激动剂（GLP-1RA）因其显著的降糖作用、减肥作用和较小的副作用，被广泛应用于 2 型糖尿病（T2DM）的治疗。一些研究表明，GLP-1RA 对前列腺癌具有抑制作用，其应用会产生与某些肿瘤风险增加或降低相关的不良反应。GLP-1R 广泛存在于人体各种类型的细胞和组织中，因此 GLP-1RA 引起了临床对肿瘤发生、发展和预后的广泛关注，为前列腺癌的治疗带来了更多新的方向和希望。本文描述了胰高血糖素样肽-1 受体（GLP-1R）在前列腺癌中的表达及胰高血糖素样肽-1 受体激动剂（GLP-1RA）对前列腺癌的作用。
Zotero 插件